Cepheid has announced the development a four-in-one test that is expected to deliver qualitative detection of SARS-CoV-2, Flu A, Flu B and RSV from a single patient sample, according to a company press release.
The Xpert Xpress SARS-CoV-2/Flu/RSV is designed for use on any GeneXpert system with results expected in as little as 35 minutes.
Cepheid said it plans to pursue an Emergency Use Authorization (EUA) pathway from the U.S. Food and Drug Administration (FDA) for regulatory authorization and make the test available globally on its cartridge-based GeneXpert Systems, which features instruments that can be configured for either point-of-care (POC) or high-volume laboratory testing needs.
